Latest Breaking News On - Treatment of cancer - Page 10 : comparemela.com

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxelPost-hoc subgroup efficacy analysis based on updated tumor subtypes in the oral paclitaxel phase III study demonstrated an improved response rate with oral paclitaxel plus encequidar across tumor subgroups BUFFALO, N.Y., June 04, 2021 (GLOBE NEWSWIRE) Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commer

Treatment of cancerPharmacokinetic studyIopharmaceutical companyResponse ratesThe company

Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Children's Hospital will present frontline data for DANYELZA and GM-CSF for consolidation of high-risk neuroblastoma (“HR-NB”) patients in complete re

Gm csfIopharmaceutical companyTreatment of cancerAmerican society of clinical oncologyComplete remissionProduct developmentJaume moraPediatric patientsCancer treatmentகம் கிசுப்பி

Curis, Inc Announces 2021 Virtual Symposium: VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond

Curis, Inc Announces 2021 Virtual Symposium: VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Treatment of cancerPadmanee sharmaRandolph noelleNorris cotton cancer centerVirtual symposiumD anderson cancer centerசிகிச்சை ஆஃப் புற்றுநோய்ட ஆண்டர்சன் புற்றுநோய் மையம்

PCI Biotech: US patent for the vaccine technology (fimaVacc) in combination with checkpoint inhibitors

Oslo (Norway), 31 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a new US patent will be granted early June 2021. The US patent covers the use of fimaVacc in combination with immune checkpoint inhibitors (ICIs). The use of ICIs has revolutionised cancer immunotherapy, as this class of drugs may induce long-lasting effects in those patients responding to treatment. Unfortunately, most patients do not respond to ICI therapy and different treatment combination strategies are explored with the aim to increase the number of patients responding. Combining ICIs with therapeutic cancer vaccines that induce relevant immune responses against the tumour cells is regarded as one of the most promising strategies. The patent that soon will be granted in the US covers the use of PCI Biotech’s fimaVacc vaccination technology in combination with important classe

Immune responsesCancer vaccinesCellular immune responsesTreatment of cancerImmune checkpoint inhibitorsநோய் எதிர்ப்பு சக்தி பதில்கள்

PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer

PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Bile duct cancerSouth koreaBile ductTreatment of cancerUnmet medical needIopharmaceutical company